Abstract

Lung cancers represent a more large landscape than well-known histological categories including lung adenocarcinoma (45% of cases), squamous cell carcinoma (25%), large cell carcinoma (10%) and small cell lung carcinoma (20%). Since 2004, when epidermal growth factor receptor (EGFR) mutations were discovered to give sensitivity to tyrosine kinase inhibitors (TKIs) in lung adenocarcinomas, developments had showed that lung cancer are molecularly distinct with different therapeutic vulnerabilities (1).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.